

[R₁ and] R₃ [are] is selected [independently] from the group consisting of optionally substituted hydroxyaryls and alkoxyaryls;


R₂ is selected from the group consisting of [hydrogen and] optionally substituted loweralkyls; and

R₄ is selected from the group consisting of optionally substituted cycloalkyls.

2. (Amended) The compound of claim 1, wherein [R₁ and] R₃ [are] is selected [independently] from the group consisting of optionally substituted hydroxyaryls.

3. (Amended) The compound of claim 1, wherein [R₁ and] R₃ [are] is selected [independently] from the group consisting of optionally [substituted] substituted alkoxyaryls.

5. (Amended) [The compound of claim 1, wherein] A compound having a formula selected from the group consisting of:



and its pharmaceutically acceptable salts, wherein:

R₁ is optionally substituted *para*-hydroxyphenyl;

[at least one of R₁ and] R₃ is selected [independently] from the group consisting of optionally substituted phenoxyloweralkyls;

R₂ is selected from the group consisting of optionally substituted loweralkyls; and

R₄ is selected from the group consisting of optionally substituted cycloalkyls.

7. (Amended) The compound of claim 6, wherein at least one of R₁ and R₃ is substituted with a [substituten] substituent selected [fromn] from the group consisting of halogen, nitro, cyano, loweralkyl, haloloweralkyl, loweralkyloxy, haloloweralkyloxy, carboxy, loweralkylthio, aminocarbonyl, and loweralkylsulfinyl.